子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种微生物的检测识别方法和系统 | CN201611213197.2 | 2016-12-23 | CN106650311A | 2017-05-10 | 刘恩浩 |
| 本发明适用于生物工程领域，提供了一种微生物的检测识别方法和系统，所述方法包括下述步骤：采用高通量的测序技术对从环境样本中提的DNA进行测序，得到DNA标签序列；去除所述DNA标签序列中存在的载体污染；将所述DNA标签序列与已知数据库中的已知序列进行比对，并根据比对结果确定所述DNA标签序列的所属分类。本发明实施例可以检测到环境样本中可能存在哪些微生物物种或哪一类微生物物种。 | ||||||
| 2 | 一种齿兰环斑病毒分离物分子鉴定的方法 | CN201410679529.0 | 2014-11-24 | CN104450958A | 2015-03-25 | 乙引; 洪鲲; 万晴姣; 张宇斌 |
| 一种齿兰环斑病毒分离物分子鉴定的方法，通过ELISA方法从蝴蝶兰检测到齿兰环斑病毒ORSV-GZ，利用其枯斑寄主苋色黎进行纯化，RT-PCR扩增该病毒外壳蛋白CP基因并将其克隆至pMD18-T载体后测序并进行核苷酸序列分析。本发明从分子水平对ORSV蝴蝶兰分离物进行鉴定，完成了该病毒分离物的分子鉴定，为兰花病毒的检测、防控及兰花种质资源的保护提供理论基础。 | ||||||
| 3 | 一种微生物的检测识别方法和系统 | CN201611134833.2 | 2016-12-11 | CN106555008A | 2017-04-05 | 李寿乐 |
| 本发明适用于生物工程领域，提供了一种微生物的检测识别方法和系统，所述方法包括下述步骤：采用高通量的测序技术对从环境样本中提的DNA进行测序，得到DNA标签序列；去除所述DNA标签序列中存在的载体污染；将所述DNA标签序列与已知数据库中的已知序列进行比对，并根据比对结果确定所述DNA标签序列的所属分类。本发明实施例可以检测到环境样本中可能存在哪些微生物物种或哪一类微生物物种。 | ||||||
| 4 | 纤维变性易感性IL22RA2基因及其用途 | CN201280047401.1 | 2012-08-03 | CN104302780A | 2015-01-21 | 阿莱恩·德赛因; 马蒂厄·塞尔托里奥; 劳伦特·阿尔吉罗 |
| 本发明公开了纤维变性易感性基因座IL22RA2基因座的鉴定，所述基因座可用于纤维变性的易感性检测、诊断和预后以及治疗活性药物的筛选。本发明还提供了用于确定患有病毒感染的患者对使用抗病毒剂和/或干扰素的治疗做出响应的可能性的方法，所述方法包括确定所述患者的生物样品中IL22RA2基因座中、或IL22RA2表达或IL22RA2蛋白活性中的变化。 | ||||||
| 5 | 纤维变性易感性IL22RA2基因及其用途 | CN201280047401.1 | 2012-08-03 | CN104302780B | 2017-04-12 | 阿莱恩·德赛因; 马蒂厄·塞尔托里奥; 劳伦特·阿尔吉罗 |
| 本发明公开了纤维变性易感性基因座IL22RA2基因座的鉴定，所述基因座可用于纤维变性的易感性检测、诊断和预后以及治疗活性药物的筛选。本发明还提供了用于确定患有病毒感染的患者对使用抗病毒剂和/或干扰素的治疗做出响应的可能性的方法，所述方法包括确定所述患者的生物样品中IL22RA2基因座中、或IL22RA2表达或IL22RA2蛋白活性中的变化。 | ||||||
| 6 | 监测家禽保种效果的SNP标记筛选方法及其在鸡保种上的应用、以及SNP标记的鉴定方法 | CN201610601296.1 | 2016-07-28 | CN106434867A | 2017-02-22 | 韩威; 苏一军; 李国辉; 王洪志; 朱云芬; 盛中伟; 张会永; 殷建玫; 邹剑敏 |
| 本发明涉及一种监测家禽保种效果的高密度SNP分子标记筛选方法及其在鸡种保种上的应用、以及SNP分子标记的鉴定方法。选取若干同类家禽品种，每个家禽品种选取若干个体，按照以下方法筛选SNP：1）所有家禽品种共有，各SNP位点在任一品种中至少存在两个等位基因；2）在基因组上分布相对集中，SNP位点数量在基因组1M 区间内 >90个；3）遗传多样性较为丰富，各SNP位点在任一品种中的最小等位基因频率 >0.1；筛选得到满足上述1）、2）、3）要求的SNP位点。本发明提供一种利用简化基因组RAD-seq测序技术对不同地方鸡种进行测序，通过序列比对，鉴定出在不同鸡种基因组上集中分布、遗传多样性较为丰富的一致性SNP位点。 | ||||||
| 7 | 用于路易体痴呆的诊断的遗传标志物 | CN201280037874.3 | 2012-07-30 | CN103764846A | 2014-04-30 | K·拜尔; 蒙特塞拉特·多明戈; 奥雷利奥·阿里萨 |
| 发现了在BChE基因中的特异多态性，其允许确定患者是否患有路易体痴呆（DLB），并且允许区分路易体痴呆与阿尔茨海默病。本发明提供了一种用于DLB的诊断的体外方法，其包括确定来自被试者生物样品内的在丁酰胆碱酯酶（BChE）基因中的以下多态性的基因型：在NCBI登录号NG_009031（即SEQ？ID？NO:1）内的位置3687处的多态位点，在SEQ？ID？NO:1内的位置4206处的多态位点，在SEQ？ID？NO:1内的位置4443处的多态位点，以及在NCBI登录号NG_009031内的位置68974（即SEQ？ID？NO:26内的位置934）处的多态位点。 | ||||||
| 8 | Cancer profile | JP2003558209 | 2003-01-09 | JP2005532036A | 2005-10-27 | 祐輔 中村; 保行 大西; 豊雅 片桐 |
| 本発明は、遺伝的プロフィールおよび癌のマーカーに関し、特定の患者および癌のタイプに有効である薬物をスクリーニングするための系および方法を提供する。 特に本発明は、個々の癌にカスタマイズされた個人化された治療を提供する。 | ||||||
| 9 | TWO-DIMENSIONAL CELL ARRAY DEVICE AND APPARATUS FOR GENE QUANTIFICATION AND SEQUENCE ANALYSIS | EP13878277.6 | 2013-03-12 | EP2975123B1 | 2018-01-10 | SHIRAI, Masataka; KAMBARA, Hideki; TANIGUCHI, Kiyomi; TANABE, Maiko |
| In order to conduct gene expression analysis of a number of genes in a number of cells, it has been necessary to separate cells, extract genes therefrom, amplify nucleic acids, and perform sequence analysis. However, separation of cells imposes damages on the cells, and it requires the use of an expensive system. Gene expression analysis in each cell can be carried out with high accuracy by arranging a pair of structures comprising a cell trapping section and a nucleic acid trapping section in a vertical direction to extract individual genes in relevant cells, synthesizing cDNA in the nucleic acid trapping section, amplifying nucleic acids, and analyzing the sequences using a next-generation sequencer. | ||||||
| 10 | TWO-DIMENSIONAL CELL ARRAY DEVICE AND APPARATUS FOR GENE QUANTIFICATION AND SEQUENCE ANALYSIS | EP13878277 | 2013-03-12 | EP2975123A4 | 2016-11-30 | SHIRAI MASATAKA; KAMBARA HIDEKI; TANIGUCHI KIYOMI; TANABE MAIKO |
| In order to conduct gene expression analysis of a number of genes in a number of cells, it has been necessary to separate cells, extract genes therefrom, amplify nucleic acids, and perform sequence analysis. However, separation of cells imposes damages on the cells, and it requires the use of an expensive system. Gene expression analysis in each cell can be carried out with high accuracy by arranging a pair of structures comprising a cell trapping section and a nucleic acid trapping section in a vertical direction to extract individual genes in relevant cells, synthesizing cDNA in the nucleic acid trapping section, amplifying nucleic acids, and analyzing the sequences using a next-generation sequencer. | ||||||
| 11 | DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS | US16288416 | 2019-02-28 | US20190194759A1 | 2019-06-27 | Joshua BABIARZ; Tudor Pompiliu CONSTANTIN; Lane A. EUBANK; George GEMELOS; Matthew Micah HILL; Huseyin Eser KIRKIZLAR; Matthew RABINOWITZ; Onur SAKARYA; Styrmir SIGURJONSSON; Bernhard ZIMMERMANN |
| The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus. | ||||||
| 12 | METHODS RELATING TO LUNG CANCER | US15877447 | 2018-01-23 | US20180207196A1 | 2018-07-26 | Ana Brandusa Pavel; Joshua David Campbell; Marc Elliott Lenburg; Avrum Spira |
| The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs. | ||||||
| 13 | Two-dimensional cell array device and apparatus for gene quantification and sequence analysis | US14771339 | 2013-03-12 | US10030240B2 | 2018-07-24 | Masataka Shirai; Hideki Kambara; Kiyomi Taniguchi; Maiko Tanabe |
| In order to conduct gene expression analysis of a number of genes in a number of cells, it has been necessary to separate cells, extract genes therefrom, amplify nucleic acids, and perform sequence analysis. However, separation of cells imposes damages on the cells, and it requires the use of an expensive system. Gene expression analysis in each cell can be carried out with high accuracy by arranging a pair of structures comprising a cell trapping section and a nucleic acid trapping section in a vertical direction to extract individual genes in relevant cells, synthesizing cDNA in the nucleic acid trapping section, amplifying nucleic acids, and analyzing the sequences using a next-generation sequencer. | ||||||
| 14 | METHOD FOR PREDICTING RESPONSE OR PROGNOSIS OF LUNG ADENOCARCINOMA WITH EGFR-ACTIVATING MUTATIONS | US14131182 | 2012-07-05 | US20140242580A1 | 2014-08-28 | Sung-liang Yu; Pan-chyr Yang; Shinsheng Yuan; Gee-chen Chang; Hsuan-yu Chen; Ker-chau Li |
| The invention provides a method for predicting the response of an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a method for predicting prognosis in an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with EGFR-TKI. In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis. | ||||||
| 15 | Nucleic acid-based logic circuits | US11490948 | 2006-07-21 | US07745594B2 | 2010-06-29 | Georg Seelig; David Soloveichik; Erik Winfree; David Zhang |
| This invention relates to nucleic acid-based logic gates. The invention further relates to circuits comprising nucleic acid-based logic gates and methods of performing operations with the gates and circuits provided herein. | ||||||
| 16 | MOLECULAR METHODS FOR ASSESSING POST KIDNEY TRANSPLANT COMPLICATIONS | US15756488 | 2016-08-30 | US20180265914A1 | 2018-09-20 | Taku Murakami; Cindy M. Yamamoto; Masato Mitsuhashi; Hiroshi Harada |
| The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various post-kidney transplant complications. In particular, annexin1 mRNA expression patterns are analyzed through a unique diagnostic formula. | ||||||
| 17 | MOLECULAR METHODS FOR ASSESSING POST KIDNEY TRANSPLANT COMPLICATIONS | US15453851 | 2017-03-08 | US20170184575A1 | 2017-06-29 | Taku Murakami; Cindy Yamamoto; Masato Mitsuhashi; Hiroshi Harada |
| Methods of screening for expression of an RNA associated with a post-kidney transplant complication include collecting vesicles from urine, isolating vesicle-associated RNA, and analyzing expression patterns. In particular, AIF1, BTN3A3, CCL5, CD48, HAVCR1, or SLC6A6 mRNA expression patterns are analyzed. | ||||||
| 18 | REDUCTION OF BIAS IN GENOMIC COVERAGE MEASUREMENTS | US15117689 | 2015-02-24 | US20160355873A1 | 2016-12-08 | Zeljko Dzakula |
| Methods are provided for detecting and quantitating molecules using fluidics. In some embodiments, the methods comprise minimizing or eliminating biases caused by label density, or minimizing or eliminated biases caused by factors other than label density. In some embodiments, the methods comprise automated identification of genetic structural variation. In some embodiments, the methods comprise analyzing blood to detect the presence of circulating DNA or cells from a fetus or tumor. | ||||||
| 19 | FIBROSIS SUSCEPTIBILITY IL22RA2 GENE AND USES THEREOF | US14236869 | 2012-08-03 | US20140295427A1 | 2014-10-02 | Alain Dessein; Mathieu Sertorio; Laurent Argiro |
| The present invention discloses the identification of a fibrosis susceptibility gene locus, the IL22RA2 gene locus, which can be used for detecting predisposition to, diagnosis and prognosis of fibrosis as well as for the screening of therapeutically active drugs. The invention further provides a method for determining the likelyhood of a patient affected with a viral infection to respond to a treatment with an antiviral agent and/or an interferon, which method comprises determining alteration in IL22RA2 gene locus or in IL22RA2 expression or IL22RA2 protein activity in a biological sample of the patient. | ||||||
| 20 | Cancer profiles | US10339533 | 2003-01-09 | US20030165954A1 | 2003-09-04 | Toyomasa Katagiri; Yasuyuki Ohnishi; Yusuke Nakamura |
| The present invention relates to genetic profiles and markers of cancers and provides systems and methods for screening drugs that are effective for specific patients and types of cancers. In particular, the present invention provides personalized treatment customized to an individual's cancer. | ||||||
QQ群二维码
意见反馈
意见反馈